# Junta clínica — PT-pseudo_cac2563c222a (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_cac2563c222a",
  "pid": "PT-pseudo_cac2563c222a",
  "task": 1,
  "psa": 4.53,
  "age": 50,
  "months": 3,
  "pirads": "5",
  "psad": 0.12,
  "psav": 0.54,
  "psap": 4.1,
  "vol": 41.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.84312165,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.53 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 41 mL. csPCa 0.84.",
  "pmhx": [],
  "allergies": [
    "NSAIDs"
  ],
  "vitals": {
    "weight": "86 kg",
    "height": "182 cm",
    "bmi": "26.0",
    "bp": "143/64 mmHg",
    "hr": "64 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "28 Feb 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested to review a previous prostate biopsy alongside a steadily climbing PSA curve."
    },
    {
      "s": "History",
      "t": "A 50-year-old freelance translator residing with his wife came under scrutiny after a PSA elevation emerged in mid-2023. He denies any lower urinary tract complaints, recording an IPSS of 1 out of 35, and reports no pelvic discomfort or blood in the urine. A non-smoker, he drinks roughly 26 alcoholic units each week and stays physically active through weekend hiking excursions. Unrelated recent visits included a dermatology check for actinic keratosis monitoring and a routine flu shot given by the practice nurse. He has never undergone major operations, uses no daily prescriptions, and handles remote work using enlarged print because of mild vision loss. Despite some mild worry about the PSA curve, he feels otherwise healthy. The prior biopsy bucket is Positive."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and symmetrically normal; mobility: unrestricted; asymmetry: absent. General inspection shows stable vital signs, clear peripheral lymph nodes, and no skeletal tenderness. Abdominal palpation confirms a soft, non-tender cavity devoid of masses."
    }
  ],
  "occupation": "freelance translator",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check",
    "GP practice nurse — flu vaccination"
  ],
  "alcohol": "26 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 1/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_cac2563c222a
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 50-year-old male
  - PSA: 4.53 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 0.54 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 41.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84312165 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NSAIDs
  - Additional notes: PSA 4.53 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 41 mL. csPCa 0.84.

Vitals: weight 86 kg, height 182 cm, BMI 26.0, BP 143/64 mmHg, HR 64 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested to review a previous prostate biopsy alongside a steadily climbing PSA curve.

History: A 50-year-old freelance translator residing with his wife came under scrutiny after a PSA elevation emerged in mid-2023. He denies any lower urinary tract complaints, recording an IPSS of 1 out of 35, and reports no pelvic discomfort or blood in the urine. A non-smoker, he drinks roughly 26 alcoholic units each week and stays physically active through weekend hiking excursions. Unrelated recent visits included a dermatology check for actinic keratosis monitoring and a routine flu shot given by the practice nurse. He has never undergone major operations, uses no daily prescriptions, and handles remote work using enlarged print because of mild vision loss. Despite some mild worry about the PSA curve, he feels otherwise healthy. The prior biopsy bucket is Positive.

Physical examination: DRE — texture: smooth and symmetrically normal; mobility: unrestricted; asymmetry: absent. General inspection shows stable vital signs, clear peripheral lymph nodes, and no skeletal tenderness. Abdominal palpation confirms a soft, non-tender cavity devoid of masses.

Patient info: freelance translator; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 26 units / week; exercise Hiking on weekends; IPSS score: 1/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; GP practice nurse — flu vaccination.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.17 (95% CI 0.21-0.88); among patients it cannot tell apart the outcome was 0.99 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a stable MRI (PRECISE 1-3) with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy in patients with low-risk disease. It also notes that a PSA change alone should not change management based on its weak link with grade progression.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's bid of 0.55 is blind to the critical interplay between the PI-RADS score and the PSA density, which the guideline uses to guide risk-adapted biopsy decisions. It fails to account for the specific risk stratification matrix that the guideline suggests should be applied.

WHAT WE STILL NEED
The mpMRI prose - does it compare against an earlier study? if the lesion is unchanged the guideline does not support re-sampling; if new or larger it does
The PSA density - does it compare against a threshold? the guideline uses PSA-D (< 0.15ng/mL/cc) as a threshold to guide decisions.
The prior biopsy status - does it compare against a prior finding? the guideline notes that two consecutive negative biopsies lower the likelihood of a positive third biopsy.
The PSA trajectory - does it compare against a trajectory? the guideline states that a PSA change alone should not change management based on its weak link with grade progression.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on the specific details of the mpMRI prose and the PSA density relative to the guideline thresholds.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares the current lesion against an earlier study.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose compare the current lesion against an earlier study?
  Q2. Does the PSA density compare against the guideline threshold of < 0.15 ng/mL/cc?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose compares the current lesion against an earlier study by stating, "Follow-up assessment after an earlier prostate biopsy."

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not explicitly name a question that justified it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure).

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose indicates a follow-up assessment after an earlier biopsy.
The prostate volume is 41.0 mL.
AGAINST sampling this patient now
The prior biopsy was positive, meaning the tissue diagnosis is already established.

WHERE THIS LEANS
The findings suggest that the imaging findings are stable or follow-up, and the prior biopsy status is a key factor, leaning towards defer.
LEAN: defer

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar answered Q1 by stating the mpMRI prose compares the current lesion against an earlier study, but did not answer Q2 regarding the PSA density threshold.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence leans towards the classifier's suggestion of BIOPSY (0.55) by highlighting the follow-up nature of the imaging, but the evidence also strongly supports the cohort's finding of deferral due to the prior positive biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose compare the current lesion against an earlier study? Answered by the registrar via the radiology_report, which states it does.
Q2. Does the PSA density compare against the guideline threshold of < 0.15 ng/mL/cc? Not answered; the laboratory_results document remains closed.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the prior biopsy status, which is a key factor because the tissue diagnosis is already established, and the mpMRI prose, which matters because it indicates a follow-up assessment. The guideline does not explicitly support the leaning towards deferral based on these factors alone without addressing the PSA density threshold.

MY SUGGESTION TO THE CHAIR
Given that the prior biopsy is positive, the evidence leans towards deferral, but the lack of information on the PSA density threshold prevents a firm decision according to the EAU guideline.

VERDICT: not-ready | SUGGEST: defer | MISSING: laboratory_results

[The conference reopens for pass 2: 'laboratory_results' is named as missing and is still closed.]

## Intervención 9 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 2

We need the laboratory results to determine if the PSA density meets the guideline threshold, which is the remaining open question.

We are reopening (pass 2). This is what the verifier says is still missing, and how I want it closed.

REGISTRAR — nothing further to pull up: either the panel settles this or the documents worth opening are already open. Do not open anything else.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the PSA density compare against the guideline threshold of < 0.15 ng/mL/cc?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 10 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 2

WHAT I FOUND
radiology_report
The mpMRI prose compares the current lesion against an earlier study by stating, "Follow-up assessment after an earlier prostate biopsy."

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not explicitly name a question that justified it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure).

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose indicates a follow-up assessment after an earlier biopsy.
The prostate volume is 41.0 mL.
AGAINST sampling this patient now
The prior biopsy was positive, meaning the tissue diagnosis is already established.

WHERE THIS LEANS
The findings suggest that the imaging findings are stable or follow-up, and the prior biopsy status is a key factor, leaning towards defer.
LEAN: defer

## Intervención 11 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 2

SUFFICIENCY
The registrar has answered the previous question regarding the mpMRI prose, but has not addressed the moderator's question regarding the PSA density threshold.

ALIGNMENT WITH THE CLASSIFIER
The evidence leans against the classifier's suggestion of BIOPSY (0.55) by emphasizing the established prior positive biopsy, although the lack of data on PSA density prevents a definitive alignment.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the PSA density compare against the guideline threshold of < 0.15 ng/mL/cc? Not answered; the laboratory_results document remains closed.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the prior biopsy status, which matters because the tissue diagnosis is established, and the PSA density threshold, which matters because the EAU guideline uses it to guide risk-adapted biopsy decisions. The guideline does not support the leaning towards deferral based on the established prior diagnosis alone without this data.

MY SUGGESTION TO THE CHAIR
Given that the prior biopsy is positive, the evidence leans towards deferral, but the lack of information on the PSA density threshold prevents a firm decision according to the EAU guideline.

VERDICT: not-ready | SUGGEST: defer | MISSING: laboratory_results

[The conference reopens for pass 3: 'laboratory_results' is named as missing and is still closed.]

## Intervención 12 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 3

We still need the laboratory results to determine if the PSA density meets the guideline threshold, which is the remaining open question.

We are reopening (pass 3). This is what the verifier says is still missing, and how I want it closed.

REGISTRAR — nothing further to pull up: either the panel settles this or the documents worth opening are already open. Do not open anything else.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the PSA density compare against the guideline threshold of < 0.15 ng/mL/cc?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 13 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 3

WHAT I FOUND
radiology_report
The mpMRI prose compares the current lesion against an earlier study by stating, "Follow-up assessment after an earlier prostate biopsy."

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not explicitly name a question that justified it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure).

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose indicates a follow-up assessment after an earlier biopsy.
The prostate volume is 41.0 mL.
AGAINST sampling this patient now
The prior biopsy was positive, meaning the tissue diagnosis is already established.

WHERE THIS LEANS
The findings suggest that the imaging findings are stable or follow-up, and the prior biopsy status is a key factor, leaning towards defer.
LEAN: defer

## Intervención 14 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 3

SUFFICIENCY
The registrar has answered the question regarding the mpMRI prose, but has not addressed the moderator's question regarding the PSA density threshold.

ALIGNMENT WITH THE CLASSIFIER
The evidence leans against the classifier's suggestion of BIOPSY (0.55) by emphasizing the established prior positive biopsy, although the lack of data on PSA density prevents a definitive alignment.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the PSA density compare against the guideline threshold of < 0.15 ng/mL/cc? Not answered; the laboratory_results document remains closed.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the prior biopsy status, which matters because the tissue diagnosis is established, and the PSA density threshold, which matters because the EAU guideline uses it to guide risk-adapted biopsy decisions. The guideline does not support the leaning towards deferral based on the established prior diagnosis alone without this data.

MY SUGGESTION TO THE CHAIR
Given that the prior biopsy is positive, the evidence leans towards deferral, but the lack of information on the PSA density threshold prevents a firm decision according to the EAU guideline.

VERDICT: not-ready | SUGGEST: defer | MISSING: laboratory_results

[The conference closes after pass 3: no closed document is left that could answer, or the pass budget is spent. The chair decides on the record as it stands.]

## Intervención 15 — CHAIR

*the senior urologist who signs the decision* · vuelta 3

MY DECISION: NO BIOPSY   (confidence: borderline)

I defer biopsy because the prior biopsy was positive, meaning the tissue diagnosis is already established, which is a key factor. While the mpMRI indicated a follow-up assessment, the established prior diagnosis negates the need for further tissue sampling at this time. The lack of information on the PSA density threshold prevented a clear decision according to the EAU guideline, leading to a borderline conclusion.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report
